DK4054582T3 - Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter - Google Patents
Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteterInfo
- Publication number
- DK4054582T3 DK4054582T3 DK20800617.1T DK20800617T DK4054582T3 DK 4054582 T3 DK4054582 T3 DK 4054582T3 DK 20800617 T DK20800617 T DK 20800617T DK 4054582 T3 DK4054582 T3 DK 4054582T3
- Authority
- DK
- Denmark
- Prior art keywords
- capivasertib
- malignants
- acalabrutinib
- cell
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930208P | 2019-11-04 | 2019-11-04 | |
| PCT/EP2020/080493 WO2021089419A1 (en) | 2019-11-04 | 2020-10-30 | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4054582T3 true DK4054582T3 (da) | 2025-12-01 |
Family
ID=73043259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20800617.1T DK4054582T3 (da) | 2019-11-04 | 2020-10-30 | Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220401442A1 (da) |
| EP (1) | EP4054582B1 (da) |
| JP (1) | JP7575454B2 (da) |
| KR (1) | KR20220098175A (da) |
| CN (1) | CN114728003B (da) |
| AU (1) | AU2020381240C1 (da) |
| CA (1) | CA3158321A1 (da) |
| DK (1) | DK4054582T3 (da) |
| ES (1) | ES3055126T3 (da) |
| FI (1) | FI4054582T3 (da) |
| MX (1) | MX2022005250A (da) |
| PL (1) | PL4054582T3 (da) |
| PT (1) | PT4054582T (da) |
| WO (1) | WO2021089419A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023230286A2 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| AU2022486467A1 (en) * | 2022-11-15 | 2025-06-26 | Astrazeneca Ab | Therapeutic combinations of capivasertib and venetoclax |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008309383B2 (en) | 2007-10-11 | 2012-04-19 | Astrazeneca Ab | Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors |
| CA2841886C (en) | 2011-07-19 | 2016-08-16 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
| EA201690608A1 (ru) * | 2013-12-04 | 2016-12-30 | Джилид Сайэнс, Инк. | Способы лечения раковых заболеваний |
| US10328080B2 (en) * | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
| US20180353512A1 (en) * | 2015-06-23 | 2018-12-13 | Gilead Sciences, Inc. | Combination therapies for treating b-cell malignancies |
| US20170071962A1 (en) * | 2015-09-11 | 2017-03-16 | Acerta Pharma B.V. | Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor |
| JP2019500368A (ja) * | 2015-12-17 | 2019-01-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔａｎｋ結合キナーゼ阻害剤化合物 |
| CN107344940B (zh) * | 2016-05-06 | 2020-04-21 | 广东东阳光药业有限公司 | Btk抑制剂及其用途 |
| US20180141939A1 (en) * | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
| KR20200058462A (ko) * | 2017-09-25 | 2020-05-27 | 아스트라제네카 아베 | 암을 치료하기 위한 btk 억제제 및 cdk9의 억제제의 조합 |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
-
2020
- 2020-10-30 WO PCT/EP2020/080493 patent/WO2021089419A1/en not_active Ceased
- 2020-10-30 MX MX2022005250A patent/MX2022005250A/es unknown
- 2020-10-30 US US17/755,548 patent/US20220401442A1/en active Pending
- 2020-10-30 EP EP20800617.1A patent/EP4054582B1/en active Active
- 2020-10-30 JP JP2022525916A patent/JP7575454B2/ja active Active
- 2020-10-30 PT PT208006171T patent/PT4054582T/pt unknown
- 2020-10-30 PL PL20800617.1T patent/PL4054582T3/pl unknown
- 2020-10-30 DK DK20800617.1T patent/DK4054582T3/da active
- 2020-10-30 ES ES20800617T patent/ES3055126T3/es active Active
- 2020-10-30 KR KR1020227018891A patent/KR20220098175A/ko active Pending
- 2020-10-30 CA CA3158321A patent/CA3158321A1/en active Pending
- 2020-10-30 CN CN202080076132.6A patent/CN114728003B/zh active Active
- 2020-10-30 AU AU2020381240A patent/AU2020381240C1/en active Active
- 2020-10-30 FI FIEP20800617.1T patent/FI4054582T3/fi active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220098175A (ko) | 2022-07-11 |
| PT4054582T (pt) | 2025-12-10 |
| US20220401442A1 (en) | 2022-12-22 |
| FI4054582T3 (fi) | 2025-12-04 |
| CN114728003A (zh) | 2022-07-08 |
| AU2020381240B2 (en) | 2023-09-07 |
| EP4054582A1 (en) | 2022-09-14 |
| CA3158321A1 (en) | 2021-05-14 |
| ES3055126T3 (en) | 2026-02-10 |
| CN114728003B (zh) | 2025-01-28 |
| JP7575454B2 (ja) | 2024-10-29 |
| EP4054582B1 (en) | 2025-09-03 |
| AU2020381240A1 (en) | 2022-06-23 |
| AU2020381240C1 (en) | 2024-02-15 |
| WO2021089419A1 (en) | 2021-05-14 |
| JP2023501317A (ja) | 2023-01-18 |
| MX2022005250A (es) | 2022-06-08 |
| PL4054582T3 (pl) | 2026-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3858977T5 (da) | Stamme til forebyggelse og behandling af stofskiftesygdomme, og brugen heraf | |
| DK4065585T3 (da) | Substituerede makrocykliske forbindelser og relaterede behandlingsfremgangsmåder | |
| DK3947375T3 (da) | Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf | |
| DK3774789T3 (da) | BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse | |
| DK3902803T3 (da) | Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft | |
| DK3673080T3 (da) | Antisense-oligomerer til behandling af lidelser og sygdomme | |
| DK3784663T3 (da) | Substituerede 4-aminoisoindolin-1,3-dionforbindelser og deres anvendelse til behandlng af et lymfom | |
| DK3681500T3 (da) | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi | |
| DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK4014976T3 (da) | Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan | |
| DK3442580T3 (da) | Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
| DK3341001T3 (da) | Sammensætning og fremgangsmåde til behandling og profylakse af tarminfektion og -inflammation | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| DK3807316T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer | |
| DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
| DK4021487T5 (da) | Antigene peptider til forebyggelse og behandling af b-celle malignitet | |
| GB201813312D0 (en) | Compounds and their therapeutic use | |
| DK3615502T3 (da) | Terapeutiske forbindelser og fremgangsmåder | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| DK4125842T3 (da) | Samtidig indgivelse af mirdametinib og lifirafenib til anvendelse til behandling af kræftformer | |
| DK3710590T3 (da) | Virale vektorer omfattende rdh12-kodende områder og fremgangsmåder til behandling af nethindedystrofier |